Showing results (351-360 of 385) with videos related to

Sort By:
Pageof 39
Nature Communications|March 30, 2024
Alignment of brain embeddings and artificial contextual embeddings in natural language points to common geometric patternsAriel Goldstein, Avigail Grinstein-Dabush, Mariano Schain, et al.
The New England Journal of Medicine|May 15, 2007
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseasesSuzanne M Garland, Mauricio Hernandez-Avila, Cosette M Wheeler, et al.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trialMark Sulkowski, Christophe Hezode, Jan Gerstoft, et al.
Hepatology Communications|May 16, 2018
Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infectionJacob George, Eduard Burnevich, I-Shyan Sheen, et al.
Nature|April 10, 2015
Measurement of the first ionization potential of lawrencium, element 103T K Sato, M Asai, A Borschevsky, et al.
American Journal of Human Genetics|January 13, 2000
A cholesterol-lowering gene maps to chromosome 13qH Knoblauch, B Müller-Myhsok, A Busjahn, et al.
The Journal of Chemical Physics|July 23, 2021
Systematic study and uncertainty evaluation of P, T-odd molecular enhancement factors in BaFPi A B Haase, Diewertje J Doeglas, Alexander Boeschoten, et al.
Journal of Hepatology|August 21, 2016
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trialJan Sperl, Gabor Horvath, Waldemar Halota, et al.
Hepatology (Baltimore, Md.)|February 24, 2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trialGraham R Foster, Kosh Agarwal, Matthew E Cramp, et al.
Annals of Internal Medicine|August 8, 2022
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort StudyJason Grebely, Gregory J Dore, Frederick L Altice, et al.
Pageof 39